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ABSTRACT:
The Polyomavirus BK (BKV) has been proposed to be one of the possible co-
factors in the genesis of prostate cancer (PCa) but, so far, the only convincing 
suggestion is the hypothesis of a “hit and run” carcinogenic mechanism induced by 
the virus at early stages of this disease. To support this hypothesis we conducted an 
updated systematic review on previous studies regarding the association between BKV 
and PCa, in order to interpret the contrasting results and to explore whether there 
might be a significant virus-disease link. This updated analysis provides evidence for 
a significant link between BKV expression and PCa development, particularly between 
the BKV infection and the cancer risk. Forthcoming scientific efforts that take cue from 
this study might overcome the atavistic and fruitless debate regarding the BKV-PCa 
association.
Polyomavirus BK and prostate cancer; an 
unsolved dilemma
Prostate cancer (PCa) is the third most common 
cause of morbidity and the fourth leading cause of 
cancer death in western countries [1], but it is becoming 
increasingly more relevant worldwide due to higher life 
expectancy and refinement of diagnostic procedures 
[2, 3]. Among other consistent risk factors [4-6], 
the pathogenesis of this malignancy reflects chronic 
inflammatory states and the proliferative inflammatory 
atrophy (PIA) has been postulated to be the key transition 
step toward overt PCa [7]. Infectious agents have been 
ranked among inflammatory-related factors that are 
important for PCa onset [8]. This also includes viruses that 
presumably play a causative role in PIA development [9]. 
However, virus involvement in prostate carcinogenesis 
remains to be demonstrated [10]. Human Polyomavirus 
BK (BKV) is a circular double stranded DNA virus that 
belongs to the Polyomaviridae family [11]. It establishes a 
life-long persistent asymptomatic infection in the urinary 
tract latently residing in the urothelium [12]. Both human 
and cellular immune responses mounted against capsid 
antigens patrol the viral activity in immumocompetent 
individuals but the balance between immune defence 
and viral fitness is mainly due to cellular immune 
responses when reactivations occur [13, 14], particularly 
at sites of smoldering infections [15]. However, when 
the immune system is compromised following an 
ablative therapy before organ transplantation, after 
HIV associated immunosuppression or pharmacologic 
immunosuppression, this immune balance is lost and 
the viral reactivation leads to a productive infection in 
permissive cells with the release of new virions in the 
peripheral blood (viremia) and their shedding in the 
urine (viruria) [16, 17]. The increase in rate and level 
of BKV replication might lead to severe diseases at the 
anatomical site of relevance, such as the hemorrhagic 
cystitis in bladder and/or the polyomavirus-associated 
nephropathy (PVAN) in kidney, which is the principal 
cause of the transplant rejection of the organ [18, 19]. In 
contrast, the viral entry in non-permissive cells can lead 
to an oncogenic transformation as a consequence of an 
abortive infection [20]. 
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Although several oncogenic viruses have already 
been linked to human malignancies [21], such as 
papillomavirus (HPV) to cervical and anogenital cancer 
[22], Epstein-Barr virus (EBV) to Burkitt’s lymphoma [23] 
and nasopharyngeal carcinoma [24, 25], the confirmation 
of the effects of polyomaviruses in the genesis of human 
cancers, except for Merkel Cell polyomavirus and Merkel 
Cell carcinoma [26], has proven more difficult. This in 
turn rendered the acceptance of a causal role of these 
viruses in the etiology of human cancers much harder. 
The oncogenic activity of polyomaviruses has been 
documented in vitro in cell lines [27] and in hamsters 
[28]. It is exerted through the main regulatory protein 
L-Tag which binds products of tumor suppressor genes 
(pRb family, p53) thus interfering with the strategic 
checkpoints of the cell cycle of infected cells [29]. In 
addition, the p53/L-Tag complex binds and activates the 
insulin-like growth factor 1 (IGF-1) thus potentiating 
the cancer transformation of infected cells [30]. Indeed, 
it has lately been proposed that the main hallmark of the 
polyomavirus involvement in cancer development might 
be the presence of the wt-p53/L-Tag complexes in the 
cytoplasm of transformed cells. This complex appears 
after the binding of L-Tag to the wt-p53 in the nucleous 
of infected cells and the sequestration of the suppressor 
protein in their cytoplasm [31]. This might suggest the 
ranking of BKV L-Tag among the wider range of tumor 
inducers as a potential co-factor for PCa development 
[9]. Despite evidence of DNA detection and expression 
of viral gene products in pre-cancerous/cancerous lesions 
of the prostate, discrepancies between polyomavirus BK 
infection of the organ and the onset of human prostate 
cancer are still ruling the scientific discussion [32]. Is this 
investigation thus worth the efforts if there might not be 
any solid scientific ground? 
A narrow borderline between BKV behavior 
as a co-factor or bystander: the “hit and run” 
hypothesis
Plenty of work is required to discover the molecular 
mechanism underlying the viral oncogenic activity [33] 
and to understand how oncogenic viruses interfere with 
and orchestrate the tumor microenvironment [34, 35]. 
The “hit and run hypothesis” is the most valid proposition 
to justify a co-factorial role of BKV in PCa onset and 
progression [9]. It has been introduced by Skinner in 1976 
[36] and re-proposed by Galloway in 1983 [37] to stress 
the oncogenic potential of human herpes viruses (HSV) 
in cervical cancer and recently by Stevenson to provide 
experimental support [38]. The hypothesis also helps to 
explain the disparity between the gene expression of BKV 
L-Tag in prostatic tumor specimens and its rare expression 
at protein level in same specimens (Fig 1). It thus seems 
that the ability of polyomavirus to interfere with the cell 
cycle could induce the infected cells to reach the critical 
point of no return during oncogenic transformation [39]. 
Once the cell cycle is manipulated and the sequestration of 
p53 is accomplished by L-Tag in the context of an abortive 
infection, accumulation of gene mutations in the infected 
cells might lead to transformation without a continuous 
“support” of viral components [40, 41]. The activity of 
the virus paves the way for tumorigenic transformation 
at early stages of PCa and the presence of viral fitness in 
the tumor cells is no longer necessary to charge the tumor 
causality to the virus itself [38, 42]. Nonetheless, the “hit 
and run” theory is hard to be sustained experimentally 
due to the obvious difficulty in providing evidence for a 
resolved infection. In overt cancer, it will lead to a drastic 
reduction of sensitivity for tests detecting viral genes due 
to the complete disappearance of the virus in tumor cells 
Figure 1: Discrepancies between BKV L-Tag DNA detection and IHC in tumor specimens. A) A representative PCa tissue 
specimen, among those tested for molecular detection of BKV L-Tag DNA in Sais et al. [57], shows an evident lack of IHC staining for 
BKV L-Tag, as compared to B) a tissue specimen from a kidney transplant with virus reactivation (unpublished data provided by the 
authors). 
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[38]. To support the “hit and run” theory, in the present 
study we assessed a cumulative prevalence of BKV 
in PCa. We calculated the risk of cancer development 
with BKV infection on previous studies regarding the 
association between BKV and PCa in order to interpret 
the contrasting results and to explore whether there might 
be a significant virus-disease link. 
BKV-DNA expression in cancer specimens: 
original reports against specimens’ adjustment
According to new features of early pre-cancerous 
lesions in their progression to overt PCa [43], we 
performed an adjustment in the case group including also 
both non-neoplastic/precancerous and early-stage cancer 
lesions from cancer bearing prostate, which originally 
were attributed to the control group. This “specimens’ 
adjustment” allowed us to extend the search for virus 
expression into lesions at very early stages of PCa 
development. Consequently, in the case-control study 
we considered a “case” each tumor specimen obtained 
from PCa patients enrolled in each study and a “control” 
each specimen originating from non PCa patients, such 
as benign prostatic hyperplasia (BPH) patients or healthy 
tissues from other patients. We then particularly compared 
a standard analysis to a specific one by adding the 
adjustment of tissue samples. With this updated analysis 
we were aiming at confirming the co-factorial activity 
of polyomavirus BK in prostate cancer by categorizing 
its expression in tumor lesions into marginal, moderate 
or substantial for risk of PCa development. A limited 
Medline search for the keywords “BK virus”, “prostatic” 
and “prostate cancer” identified twenty-five papers. 
Fifteen out of the twenty-five articles met the criteria by 
using the molecular-based techniques for the detection 
of BKV DNA or proteins in tissues. The other ten were 
excluded for the following reasons: reviews (n=3) [44-
46], serological studies (n=3) [47-49], case report (n=1) 
[50], comment (n=1) [51], cell line study (n=1) [52] or 
publication in language other than English (n=1) [53]. 
Out of the fifteen articles included in the analysis, eight 
were carried out in Europe (Italy [54-56], Switzerland 
[57], UK [58], Sweden [59], Greece [60], Germany [61]), 
five in USA [9, 31, 62-64], one in Mexico [65] and one 
in Japan [66]. Due to lack of information if tests were 
performed considering one specimen as one patient (i.e. 
multiple tissue collection from each enrolled patient), 
we included each tumor tissue (case) or normal tissue 
(control) specimen analyzed for BKV-DNA expression 
in our statistic. Statistical analysis was performed with 
MedCalc software (v12.7.7). Estimations (95% CI) of 
single prevalence and pooled prevalence were determined 
by meta-analysis of either original reports or after adding 
the “specimens’ adjustment”. 
Based on the original reports, a total of 1106 
cancers, ranging from 7 to 328 (mean value=74; n=15), 
and 1068 controls, ranging from 11 to 385 (mean value 
97; n=11) were analyzed. The prevalence of BKV was 
significantly higher in cancer tissues than in the control 
tissues (p<0.0001). Indeed, the range was 0% to 84.6%, 
with an overall value of 13.2% (95% CI: 11.2%-15.9%) 
in cancers, and 0% to 57.9% with an overall value of 
5.6% (95% CI: 4.2%-7.0%) in controls (Table 1). Three 
groups collected as control specimens non neoplastic 
prostate tissues from areas surrounding cancer lesions, 
such as inflammatory/atrophic specimens adjacent to or 
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in transition to prostate adenocarcinoma and early-stage 
cancer lesions, such as high-grade (HG)-PIN [62-64]. To 
perform the adjustment, we included these specimens in 
the case group (1106 cancers) thereby increasing the total 
number of cases to 1399 (range 7-328, mean=93.3; n=15) 
while the number of controls decreased to 775 (range 12-
385, mean=96.9; n=8) after adjustment. The prevalence 
values varied from 0% to 84.6%, with an overall value of 
10.8% (95% CI 9.3%-12.9%) among cases and from 0% 
to 57.9% with an overall value of 6.9% (95% CI 5.1%-
8.7%) among the controls (Table 1). Overall, BKV-DNA 
was detected in about 10% of prostate tissue specimens 
tested (206/2174) in 80% of the studies (12/15) analyzed. 
Although the prevalence of BKV-DNA detection was 
obviously reduced in the case group after the adjustment, 
however not enough to be significant (original vs adjusted 
analysis p=0.08), the modest increase of percentage of 
BKV-DNA positive lesions in the adjusted group (146 to 
152 = 4%) is noteworthy since the significant association 
between viral expression and cancer observed analyzing 
the original reports is maintained when including as 
“cases” all specimens from cancer bearing prostate tested 
(p<0.01). 
BKV-DNA detection rate among techniques used 
and types of specimen tested
The methods for molecular-based testing for BKV-
DNA detection were: a) the gene assay methods using 
nested-PCR (n=9), thereof 7 with type-specific primers 
for L-Tag (n=6) or VP1 (n=1) and 2 with broad spectrum 
Figure 2:Risk of PCa with BKV infection in tumor samples compared with non-tumor prostate samples.The PCa risk 
with the presence of BKV infection was evaluated by a pooled odds ratio (OR). For measure of inter-study heterogeneity, we used 
the Cochran’s Q test. Fixed effects (Mantel-Haenszel) and random effects (DerSimonian and Laird) models were performed based on the 
percentage of variation across studies (I2 statistic). All p-values <0.05 were considered statistically significant.
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primers; b) regular PCR with broad-spectrum primers for 
BKV and JCV VP1 genes (n=1); c) quantitative real time 
PCR with specific primers and probe (qRT-PCR; n=4) 
targeting either L-Tag or VP1 genes or using a kit without 
any specification. The detection rate for BKV-DNA in 
tumor tissues by qRT-PCR (482; 44.8%) was significantly 
higher than the rate obtained by both nested and regular 
PCR (594; 55.2%) either before (20.1%; 95% CI 16.5%-
23.7% vs 7.9%; 95% CI 5.2%-9.0%, p<0.0001) or after 
the adjustment (qRT-PCR n=482; 20.1%; 95% CI 16.5%-
23.7% vs regular PCR n=818; 6.0%; 95% CI 4.5%-7.5%, 
p<0.0001) (Table 2). 
Two additional laboratory methods were employed 
to analyze BKV expression in tissue specimens. 
However, due to the limited number of specimens tested 
the calculation is reported only for completeness of 
information (data not shown). The “in situ hybridization” 
(ISH) assay employing a BKV specific probe was carried 
out in three studies (cases, n=79) [9, 31, 62], showing 
a strong prevalence of 26.6% (95% CI 11.2%-28.2%). 
For the detection of BKV proteins, four groups [9, 31, 
56, 62] employed immunohistochemistry (IHC) assays 
(cases, n=105). In particular, Das et al [9] used an anti-
VP1 Antibody (P5G6BKV9VP1) while the other groups 
identified the L-Tag protein using the antibody pAB416 
that cross reacts with SV40 and JCV. BKV proteins were 
significantly more expressed in tumor tissues (40%; 95% 
CI 30.6%-49.4%) than in normal tissues (5.6%; 95% CI 
0.12%-7.1%; p<0.0001).
Thirteen out of 15 studies mention the type of 
specimens analyzed in their “material and methods” 
section. Thus, five studies used fresh or frozen sections 
(F/F n=576, 53.6%), whereas eight studies used formalin 
fixed, paraffin embedded tissues (FFPE n=490; 46.4%). 
The efficiency at detecting BKV-DNA in FFPE tissue 
was equal to frozen sections since the detection of BKV-
DNA in FFPE tissue was 14.1% while in frozen section 
was 11.4% (p=0.23). Conversely, the difference was 
highly significant when comparing FFPE (n=559; 41.4%) 
to frozen sections (n=791; 58.6%) after the adjustment 
(13.2% vs 8.3%; p=0.003) (Table 2). The adjustment 
confirmed that qRT-PCR is the best gene assay method for 
BKV DNA detection in tissues and it supports the use of 
FFPE tissue specimens for molecular-based testing. The 
latter is of importance since, in addition to the shortage of 
prostate cancer tissues owing to increasing new therapeutic 
approaches, such as active surveillance [67], fresh/frozen 
specimens are also rarely collected for research purpose, 
due to their prioritized use for diagnostic purposes and the 
small dimensions of the tumor at first diagnosis [68].
A link between BKV expression and PCa cancer 
risk supports future investigations
Six case-control studies with 482 case tissues 
from PCa patients and 519 control tissues collected from 
patients with BPH were statistically compared for the 
estimation of BKV infection and prostate cancer risk. Two 
studies were automatically excluded after data pooling 
[59, 65], because of the absence of BKV expression in 
both cases and controls. 
The prevalence of BKV was 16.5% among the 
tissues from PCa patients (95% CI 13.8%-19.2%) and 
7.0% among the control tissues from BPH patients (95% 
CI 5.2%-8.8%; p<0.0001). According to the results of 
inter-study heterogeneity (I2 >50%), the random-effect 
model was used to evaluate the pooled OR. Overall, 
there was a significantly increased prostate cancer risk 
with the presence of BKV infection compared with the 
BPH controls (OR=3.4, 95% CI: 1.5-7.9, p=0.04; Fig. 1) 
based on an analysis assuming random models (I2 =57.6 
Q=11.8). Adding studies (n=3) using pre-cancerous 
and early-stage cancer tissues as paired controls (case 
n=632, controls n=812), an overall prostate cancer risk 
with the presence of BKV infection (OR=2.94, 95% CI 
1.51-5.73, p=0.09) was marginally maintained assuming 
random models (I2 =63.4 Q=13.7). Obviously, the case-
control analysis after the specimens’ adjustment was not 
performed due to the lack of control tissues from the three 
added studies. It is noteworthy that our analysis of the 
case-control study showed a significantly increased risk 
for PCa development only when the non-malignant control 
group consisted of BPH patients, while adding studies 
that used non neoplastic prostate tissues from PCa bearing 
patients as control reduced the risk of PCa development 
to a no longer significant value. This confirms that non-
neoplastic prostate tissues adjacent to cancer lesions or 
cancer-surrounding areas cannot be considered genuine 
controls, thus justifying the use of specimens’ adjustment 
in this analysis and future investigations. 
This link might contribute greatly to clarifying the 
role of BKV in cancer, and raise the awareness that the 
virus plays a co-factorial role rather than just being a mere 
bystander in the development of the tumor.
CONCLUSION
Prostate cancer is the most common malignancy 
affecting males and a clinically heterogeneous disease 
characterized by a variety of histological conditions that 
render the selection of pure prostatic adenocarcinoma 
from surrounding non neoplastic areas a difficult task [69]. 
In some studies used for this meta-analysis, the majority 
of positive results originated from diagnostic tests 
performed in inflammatory areas surrounding the cancer 
and/or atrophic areas at transition zones. In particular, 
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inflammation is responsible for either predisposing the 
prostate to malignant transformation by carcinogens or for 
initiating and promoting cancer generation by itself [43, 
70]. It has been postulated that BKV might be involved in 
the etiology of main precursor stages of prostate cancer, 
such as PIA, in areas where histological transitions 
between inflammation and cancer occur [9, 43]. Therefore, 
the search of BKV expression at very early stages of 
neoplastic progression, such as at PIA or PIN levels, is of 
crucial importance and adjacent tissue surrounding tumor 
areas or atrophic regions cannot be considered normal 
controls per se [71]. 
Our investigation differs from previous analyses in 
two important aspects. First it is updated to April 2014 
including four papers released in 2012 and 2013 which 
matched our selection criteria. Three of these recently 
published papers found a positive correlation between the 
expression of BKV-DNA in cancer specimens and viral 
features [54, 57, 66]. Second, we adopted a novel strategy 
in grouping cases and controls. We particularly noted 
that the adjustment of tissue sampling by including areas 
being in contact with the cancer, or tissues picked in same 
cancer bearing organs, either confirmed or improved the 
statistical significance or even made it more powerful, but 
it never worsened the situation. 
Our findings are thus consistent with a significant 
link between the BKV infection and the PCa risk. There 
is thus ample evidence for a potential co-factorial role 
of BKV in PCa. A confirmed association between the 
detection of BKV in cancer lesions, particularly in prostate 
cancer, and the malignancy could represent a first-step 
learning model on the causative role of polyomaviruses 
in cancer. This investigation is thus not an unworthy 
scientific effort, but rather deserves to be standardized 
in some ways. The gaps are mainly due to sampling 
collection schemes and selection of controls. Despite 
limited, this study might also induce new investigators to 
provide with new experimental support to understand the 
interactions between potential oncogenic viruses and the 
development of cancers. 
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